ALX Oncology's Breakthrough: Evorpacept-Zanidatamab Combination in Breast Cancer

ALX Oncology, a clinical-stage biotechnology company, has announced groundbreaking results from a Phase 1b/2 trial of its investigational combination therapy, evorpacept and zanidatamab, for treating HER2-positive and HER2-low metastatic breast cancer. The trial results will be presented at the San Antonio Breast Cancer Symposium (SABCS) 2024, highlighting the potential of this novel therapeutic approach.

The Phase 1b/2 clinical trial (NCT05027139) evaluated the safety and efficacy of the evorpacept-zanidatamab combination in patients with HER2-expressing breast cancer and other cancers. The data from this study will be summarized in a poster spotlight presentation at SABCS 2024, with Dr. Alberto J. Montero, a recognized expert in breast oncology, serving as the presenter.

Evorpacept, a highly differentiated investigational CD47 blocker, and zanidatamab, an investigational dual HER2-targeted bispecific antibody, have shown promising results in combination. The poster presentation will highlight new data from the clinical trial, evaluating the efficacy and safety of this combination therapy in patients with advanced breast cancers.

ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy in immuno-oncology. The company is currently evaluating evorpacept across multiple ongoing clinical trials in a wide range of cancer indications. The upcoming presentation at SABCS 2024 will contribute to ongoing discussions within the oncology community and showcase ALX Oncology's innovative approaches to cancer treatment.


The presentation of these trial results at SABCS 2024 could significantly influence investor sentiment and attract institutional investment in ALX Oncology. Positive results, indicating the efficacy and safety of evorpacept and zanidatamab in combination, could drive interest in ALX's stock. Historically, data presented at key conferences like SABCS have attracted institutional investors and analysts, potentially enhancing ALX's position as a front-runner in immuno-oncology.

However, investors should remain vigilant, considering the inherent risks associated with clinical-stage biotech companies. A cautious buy approach, focusing on diversifying risk and monitoring developments leading up to and after the SABCS presentation, is advisable for long-term investors.

ALX Oncology's presentation at SABCS 2024 highlights the potential of evorpacept, a CD47 blocker, in combination with zanidatamab, a dual HER2-targeted bispecific antibody, in treating HER2-positive and HER2-low metastatic breast cancer. This novel treatment approach could offer long-term benefits by targeting HER2-expressing cancers and boosting the immune system. However, risks include clinical trial uncertainties, regulatory approvals, and potential side effects.


In conclusion, ALX Oncology's upcoming presentation at SABCS 2024 showcases the potential of its innovative combination therapy, evorpacept-zanidatamab, in treating HER2-positive and HER2-low metastatic breast cancer. The trial results could significantly impact the breast cancer treatment landscape, offering a more targeted and effective approach. As investors, it is crucial to monitor the presentation at SABCS 2024 for insights into the safety profile and potential benefits of this innovative combination therapy.